Discovery Labs Announces Proposed Public Offering of Common Stock

      Discovery Labs Announces Proposed Public Offering of Common Stock

PR Newswire

WARRINGTON, Pa., Oct. 30, 2013

WARRINGTON, Pa., Oct. 30, 2013 /PRNewswire/ --Discovery Laboratories, Inc.
(Nasdaq: DSCO) today announced that it is offering to sell shares of its
common stock in an underwritten public offering.

The Company also expects to grant the underwriters a 30-day option to purchase
additional shares of common stock to cover over-allotments, if any. Stifel
and Piper Jaffray & Co. are acting as joint bookrunning managers for the
offering, Lazard Capital Markets LLC is acting as co-lead manager and Roth
Capital Partners, LLC is acting as co-manager. While the offering is expected
to price before 9:30 am EDT October 31, 2013, the offering is subject to
market conditions, and there can be no assurance as to whether or when the
offering may be completed, or as to the actual size or terms of the offering.

The securities are being offered by Discovery Laboratories, Inc. pursuant to a
registration statement previously filed and declared effective by the
Securities and Exchange Commission. The securities may be offered only by
means of a prospectus, including a prospectus supplement, forming a part of
the effective registration statement. When available, copies of the
preliminary prospectus supplement, the final prospectus supplement and the
accompanying base prospectus relating to this offering may be obtained at the
Securities and Exchange Commission web site at http://www.sec.gov, or from
Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery
Street, Suite 3700, San Francisco, California 94104 or via telephone at (415)
364-2500 or from Piper Jaffray & Co., Attention: Prospectus Department, 800
Nicollet Mall, J12S03,Minneapolis, MN55402 or by telephone at 800-747-3924
or by email at prospectus@pjc.com.

This press release shall not constitute an offer to sell or the solicitation
of an offer to buy any securities of Discovery Laboratories, Inc. nor shall
there be any sale of these securities in any state or jurisdiction in which
such offer, solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or jurisdiction.

About Discovery Labs
Discovery Laboratories, Inc. is a specialty biotechnology company focused on
advancing a new standard in respiratory critical care. Discovery Labs' novel
proprietary KL4 surfactant technology produces a synthetic, peptide-containing
surfactant that is structurally similar to pulmonary surfactant. Discovery
Labs is also developing its proprietary drug delivery technologies to enable
efficient delivery of aerosolized KL4 surfactant and other inhaled therapies.
Discovery Labs' strategy is initially focused on neonatology and improving the
management of respiratory distress syndrome (RDS) in premature infants.
Discovery Labs believes that its RDS product portfolio has the potential to
become the new standard of care for RDS and, over time, significantly expand
the current worldwide RDS market. For more information, please visit the
Company's website at www.Discoverylabs.com.

Forward-Looking Statements
To the extent that statements in this press release are not strictly
historical, all such statements are forward-looking, and are made pursuant to
the safe harbor provisions of the Private Securities Litigation Reform Act of
1995. These forward-looking statements are subject to certain risks and
uncertainties that could cause actual results to differ materially from the
statements made. Examples of such risks and uncertainties, including those
related to Discovery Labs' securities offering and its development programs,
are described in Discovery Labs' filings with the Securities and Exchange
Commission including the most recent reports on Forms 10-K, 10-Q and 8-K, and
any amendments thereto.

SOURCE Discovery Laboratories, Inc.

Website: http://www.discoverylabs.com
Contact: Company, John Tattory, Vice President of Finance, Discovery Labs -
215.488.9418, or Investor Relations: Michael Rice, LifeSci Advisors -
646.597.6979
 
Press spacebar to pause and continue. Press esc to stop.